Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Room Temperature Nanoencapsulation of Bioactive Eicosapentaenoic Acid Rich Oil within Whey Protein Microparticles

  • Escobar-García, Juan David
  • Prieto, Cristina
  • Pardo-Figuerez, Maria
  • Lagaron, José M.
[EN] In this study, emulsion electrospraying assisted by pressurized gas (EAPG) has been performed for the first time to entrap ca. 760 nm droplets of the bioactive eicosapentaenoic acid (EPA)-rich oil into whey protein concentrate (WPC) at room temperature. The submicron droplets of EPA oil were encapsulated within WPC spherical microparticles, with sizes around 5 µm. The EPA oil did not oxidize in the course of the encapsulation performed at 25 °C and in the presence of air, as corroborated by the peroxide value measurements. Attenuated Total Reflection-Fourier Transform Infrared spectroscopy and oxygen consumption tests confirmed that the encapsulated EPA-rich oil showed increased oxidative stability in comparison with the free oil during an accelerated oxidation test under ultraviolet light. Moreover, the encapsulated EPA-rich oil showed increased thermal stability in comparison with the free oil, as measured by oxidative thermogravimetric analysis. The encapsulated EPA-rich oil showed a somewhat reduced organoleptic impact in contrast with the neat EPA oil using rehydrated powdered milk as a reference. Finally, the oxidative stability by thermogravimetric analysis and organoleptic impact of mixtures of EPA and docosahexaenoic acid (DHA)-loaded microparticles was also studied, suggesting an overall reduced organoleptic impact compared to pure EPA. The results here suggest that it is possible to encapsulate 80% polyunsaturated fatty acids (PUFAs)-enriched oils by emulsion EAPG technology at room temperature, which could be used to produce personalized nutraceuticals or pharmaceuticals alone or in combination with other microparticles encapsulating different PUFAs to obtain different targeted health and organoleptic benefits., This research was funded by the MICIU (RTI-2018-097249B-C1), EU H2020-MSCA-RISE2017-778388-FODIAC and the EU H2020-EIC-SMEinst-2018-2020-SME instrument-873827-CAPSULTEK, CDTI-CIEN DANTIAN-IDI-20190954 and the CYTED thematic network (319RT0576). J.D.E.-G. wants to thank the Spanish Ministry of Economy, Industry and Competitivity for his predoctoral grant (DI-6906).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Tesis doctoral (DoctoralThesis)

Encapsulation of Underexploited Bioactives Using High Throughput Electrospray Assisted by Pressurized Gas with Application Interest in Functional Foods and Nutraceuticals

  • Escobar García, Juan David
[ES] El creciente interés por los alimentos funcionales, suplementos dietéticos y nutracéuticos se debe a la prevalencia de enfermedades crónicas y a la necesidad de soluciones de salud preventiva. Sin embargo, la incorporación de compuestos bioactivos en productos de consumo enfrenta desafíos significativos, como la degradación por factores ambientales y su limitada biodisponibilidad. La encapsulación es una estrategia clave para mejorar la estabilidad y funcionalidad de estos compuestos. Esta investigación explora el potencial de la Atomización Electrohidrodinámica Asistida por Gas Presurizado (EAPG) en la encapsulación de compuestos bioactivos infrautilizados, con un enfoque en tres sustancias: ácido eicosapentaenoico (EPA), un ácido graso omega-3; la savia de sangre de drago (DBS), una resina natural con múltiples propiedades bioactivas; y extracto de camu camu (CCX), rico en vitamina C y polifenoles. En el primer capítulo, se investigó la encapsulación del EPA utilizando EAPG con concentrado de proteína de suero (WPC) como material de recubrimiento. Se logró una mejora significativa en la estabilidad oxidativa, evidenciada en pruebas aceleradas bajo luz ultravioleta. Además, evaluaciones sensoriales en leche en polvo reconstituida confirmaron una reducción de sabores indeseables, optimizada al combinar EPA con DHA encapsulado. El segundo capítulo abordó la estabilidad y encapsulación de la DBS. Se evidenció que factores ambientales como la luz ultravioleta y la alta humedad afectan negativamente su estabilidad. Como estrategia de preservación, se comparó el secado mediante EAPG y liofilización, resultando en una mejor morfología y estabilidad para la DBS tratada con EAPG. Posteriormente, la encapsulación de DBS en WPC y zeína (ZN) permitió obtener micropartículas con mayor protección contra radiación UV y estrés ambiental, destacándose la proporción 2:1 con ZN como matriz de encapsulación. El tercer capítulo se centró en la encapsulación del CCX. El secado mediante EAPG preservó la actividad antioxidante y el contenido de polifenoles solubles totales en comparación con el CCX sin procesar. La encapsulación con WPC y ZN generó micropartículas con mayor estabilidad en condiciones de almacenamiento desafiantes, incluyendo alta humedad y exposición a radiación UV. La formulación con una proporción 2:1 de encapsulante a bioactivo mostró la mejor protección. Los resultados demuestran el potencial de la tecnología EAPG para producir micropartículas uniformes a temperatura ambiente, asegurando la preservación de compuestos sensibles al calor. Además, esta investigación resalta la importancia de los materiales de encapsulación, como WPC y ZN, en el desarrollo de soluciones personalizadas para distintos bioactivos. Más allá de su impacto tecnológico, esta metodología ofrece un enfoque escalable y rentable para la industria de alimentos funcionales y suplementos dietéticos, contribuyendo a la formulación de productos con mayor estabilidad, biodisponibilidad y aceptación por parte del consumidor., [CA] La demanda d'aliments funcionals, suplements dietètics i nutracèutics ha augmentat per la creixent prevalença de malalties cròniques i un canvi social cap a la salut preventiva. No obstant això, la incorporació de compostos bioactius en productes de consum presenta desafiaments, com la degradació ambiental i la seua limitada biodisponibilitat. L'encapsulació és una estratègia prometedora per millorar l'estabilitat i preservar la bioactivitat. Aquesta investigació explora el potencial de l'Electrospray Assistit per Gas Pressuritzat (EAPG) per encapsular compostos bioactius infrautilitzats. L'estudi se centra en tres substàncies: l'àcid eicosapentaenoic (EPA), un àcid gras omega-3; la saba de sang de drago (DBS), una resina natural amb múltiples propietats bioactives; i l'extracte de camu camu (CCX), ric en vitamina C i polifenols. En el primer capítol, l'encapsulació de l'EPA amb EAPG i concentrat de proteïna de sèrum (WPC) va millorar l'estabilitat oxidativa, com es va demostrar en proves accelerades amb llum ultraviolada. A més, una avaluació sensorial en llet en pols reconstituïda va confirmar una reducció significativa dels sabors indesitjables, especialment quan es combinava amb DHA encapsulat. El segon capítol aborda l'estabilitat, assecat i encapsulació de la DBS. Es va observar que la llum UV i la humitat elevada afecten la seua estabilitat, destacant la necessitat d'estratègies de protecció. Es va comparar l'assecat per EAPG i la liofilització, obtenint millor morfologia i estabilitat amb EAPG. Posteriorment, la DBS es va encapsular en WPC i zeïna (ZN), donant lloc a micropartícules esfèriques amb protecció superior contra la radiació UV, especialment amb una proporció 2:1 de ZN com a matriu d'encapsulació. El tercer capítol tracta sobre l'assecat i encapsulació del CCX. L'assecat per EAPG va preservar l'activitat antioxidant i els polifenols solubles totals en comparació amb el CCX sense processar. L'encapsulació amb WPC i ZN va generar micropartícules més estables en condicions d'emmagatzematge adverses, com humitat elevada i radiació UV. La formulació amb una relació 2:1 encapsulant-bioactiu va oferir la millor protecció. Els resultats destaquen la versatilitat de la tecnologia EAPG per produir micropartícules uniformes a temperatura ambient, preservant la bioactivitat de compostos sensibles a la calor. A més, es ressalta la importància dels materials d'encapsulació, com WPC i ZN, per desenvolupar solucions personalitzades segons el compost bioactiu. Aquesta investigació introdueix una metodologia escalable i rendible per a la indústria d'aliments funcionals i suplements dietètics, permetent productes amb millor estabilitat, major biodisponibilitat i més acceptació per part del consumidor., [EN] The demand for functional foods, dietary supplements, and nutraceuticals has increased due to the rising prevalence of chronic diseases and a societal shift toward preventive health solutions. However, incorporating bioactive compounds into consumer products presents challenges, including degradation from environmental stressors and limited bioavailability. Encapsulation offers a promising strategy to enhance stability and preserve bioactivity. This doctoral research explores the potential of Electrospraying Assisted by Pressurized Gas (EAPG) for encapsulating underutilized bioactive compounds. The study focuses on three bioactives: eicosapentaenoic acid (EPA), an omega-3 fatty acid; Dragon's Blood Sap (DBS), a natural resin with diverse bioactive properties; and camu camu extract (CCX), rich in vitamin C and polyphenols. In the first chapter, EPA encapsulation via EAPG with whey protein concentrate (WPC) improved oxidative stability, as confirmed by accelerated tests under UV light. Sensory evaluation in reconstituted powdered milk showed a significant reduction in undesirable off-flavors, further enhanced when combined with encapsulated DHA. The second chapter examines DBS stability, drying, and encapsulation. UV exposure and high humidity caused notable degradation, emphasizing the need for protective strategies. Freeze-drying and EAPG were compared, with EAPG providing better morphology and stability. Encapsulation of DBS in WPC and zein (ZN) resulted in spherical microparticles with superior UV protection, particularly at a 2:1 ZN-to-bioactive ratio. The third chapter focuses on CCX drying and encapsulation. EAPG drying produced irregular yet functional structures, preserving antioxidant activity and polyphenols. Encapsulation in WPC and ZN formed spherical microparticles with enhanced stability, especially at a 2:1 encapsulant-to-bioactive ratio, protecting against humidity and UV radiation. The findings highlight EAPG's versatility for producing uniform microparticles at room temperature, preserving heat-sensitive bioactives. This research underscores the critical role of encapsulation materials like WPC and ZN in developing tailored stabilization strategies. Beyond technological advances, this scalable and cost-effective methodology lays the foundation for functional food and supplement development, extending shelf life, improving bioavailability, and meeting consumer demand for clean-label products., The author would like to thank the Spanish Ministry of Economy, Industry, and Competitivity for his predoctoral grant (DI-6906). The Accreditation as Center of Excellence Severo Ochoa CEX2021-001189-S funded by MCIU/AEI/10.13039/501100011033 is also fully acknowledged. This research was funded by the MICIU (RTI-2018-097249B-C1), EU H2020-MSCA-RISE-2017-778388-FODIAC and the EU H2020-EIC-SMEinst-2018-2020-SME instrument-873827-CAPSULTEK, CDTI-CIEN DANTIAN-IDI-20190954 and the CYTED thematic network (319RT0576).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanostructured Valsartan Microparticles with Enhanced Bioavailability Produced by High-Throughput Electrohydrodynamic Room-Temperature Atomization

  • Prieto López, Cristina
  • Evtoski, Zoran
  • Pardo Figuérez, María
  • Hrakovsky, Julia
  • Lagarón Cabello, José María
The high-throughput drying and encapsulation technique called electrospraying assisted by pressurized gas (EAPG) was used for the first time to produce nanostructured valsartan within microparticles of excipients. Valsartan, a poorly absorbed and lipid-soluble drug, was selected since it is considered a good model for BCS class II drugs. Two different polymeric matrices were selected as excipients, i.e., hydroxypropyl methylcellulose (HPMC) and lactose monohydrate, while Span 20 was used as a surfactant. The produced 80% valsartan loading formulations were characterized in terms of morphology, crystallinity, in vitro release, in vitro Caco-2 cells’ permeability, and in vivo pharmacokinetic study. Spherical microparticles of ca. 4 μm were obtained within which valsartan nanoparticles were seen to range from 150 to 650 nm. Wide-angle X-ray scattering and differential scanning calorimetry confirmed that valsartan had a lower and/or more ill-defined crystallinity than the commercial source, and photon correlation spectroscopy and transmission electron microscopy proved that it was dispersed and distributed in the form of nanoparticles of controlled size. In vitro dissolution tests showed that the HPMC formulation with the lowest API particle size, i.e., 150 nm, dissolved 2.5-fold faster than the commercial valsartan in the first 10 min. This formulation also showed a 4-fold faster in vitro permeability than the commercial valsartan and a 3-fold higher systemic exposure than the commercial sample. The results proved the potential of the EAPG processing technique for the production of safe-to-handle microparticles containing high quantities of a highly dispersed and distributed nanonized BCS class II model drug with enhanced bioavailability., This research was funded by the Spanish Ministry of Science and Universities (project RTI-2018-097249-B-C1), the Valencian Innovation Agency BIOENCAP project (reference no. INNCAD00-18-31), the H2020 EU projects FODIAC (reference no. 778388), the CAPSULTEK (reference no. 873827), and the CYTED thematic network (reference no. 319RT0576)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Room Temperature Nanoencapsulation of Bioactive Eicosapentaenoic Acid Rich Oil within Whey Protein Microparticles

  • Escobar García, Juan D.
  • Prieto López, Cristina
  • Pardo Figuérez, María
  • Lagarón Cabello, José María
In this study, emulsion electrospraying assisted by pressurized gas (EAPG) has been performed for the first time to entrap ca. 760 nm droplets of the bioactive eicosapentaenoic acid (EPA)-rich oil into whey protein concentrate (WPC) at room temperature. The submicron droplets of EPA oil were encapsulated within WPC spherical microparticles, with sizes around 5 µm. The EPA oil did not oxidize in the course of the encapsulation performed at 25 °C and in the presence of air, as corroborated by the peroxide value measurements. Attenuated Total Reflection—Fourier Transform Infrared spectroscopy and oxygen consumption tests confirmed that the encapsulated EPA-rich oil showed increased oxidative stability in comparison with the free oil during an accelerated oxidation test under ultraviolet light. Moreover, the encapsulated EPA-rich oil showed increased thermal stability in comparison with the free oil, as measured by oxidative thermogravimetric analysis. The encapsulated EPA-rich oil showed a somewhat reduced organoleptic impact in contrast with the neat EPA oil using rehydrated powdered milk as a reference. Finally, the oxidative stability by thermogravimetric analysis and organoleptic impact of mixtures of EPA and docosahexaenoic acid (DHA)-loaded microparticles was also studied, suggesting an overall reduced organoleptic impact compared to pure EPA. The results here suggest that it is possible to encapsulate 80% polyunsaturated fatty acids (PUFAs)-enriched oils by emulsion EAPG technology at room temperature, which could be used to produce personalized nutraceuticals or pharmaceuticals alone or in combination with other microparticles encapsulating different PUFAs to obtain different targeted health and organoleptic benefits., This research was funded by the MICIU (RTI-2018-097249B-C1), EU H2020-MSCA-RISE-2017-778388-FODIAC and the EU H2020-EIC-SMEinst-2018-2020-SME instrument-873827-CAPSULTEK, CDTI-CIEN DANTIAN-IDI-20190954 and the CYTED thematic network (319RT0576)., Peer reviewed